Merck's Keytruda Set For Expanded Use As Lung Cancer Monotherapy

Data showing overall survival benefit for Keytruda in patients with at least 1% PD-L1 expression ups the ante for competitors Bristol and Roche, which will be presenting data for combinations in lung cancer at the American Association of Clinical Research meeting in April.

Clinical trials
NEW NSCLC DATA FOR KEYTRUDA

Merck & Co. Inc.'s PD-1 inhibitor Keytruda's(pembrolizumab) position in first-line non-small cell lung cancer (NSCLC) is now even stronger with the KEYNOTE-042 study showing the drug works well as monotherapy across levels of PD-L1 expression.

NSCLC is expected to account for close to half of the total immuno-oncology (IO) market and Keytruda has been consistently...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Immuno-oncology

More from Anticancer